. Author manuscript; available in PMC: 2019 Jan 24.

Published in final edited form as: Haemophilia. 2018 Jul 13;24(5):807–814. doi: 10.1111/hae.13565

TABLE 2.

Results of factor VIII (FVIII) inhibitor tests by Nijmegen-Bethesda assay (NBA) and chromogenic Bethesda assay (CBA), anti-FVIII antibodies by fluorescence immunoassay and lupus anticoagulant (LA) tests

Group	NBA result	Samples, N	Anti-FVIII IgG1 positive	Anti-FVIII IgG4 positive	CBA positive	LA positive
Haemophilia reference group	NBA negative	50	14 (28%)	2 (4%)	0	–
Haemophilia reference group	NBA positive	66	60 (91%)	60 (91%)	56 (85%)	2/24
Haemophilia study group	NBA negative	9	8 (89%)	8 (89%)	2 (22%)	3/5
Haemophilia study group	NBA positive	23	22 (96%)	19 (83%)	16 (70%)	9/16
Non-haemophilia study group	NBA negative	29	3 (10%)	0	2 (7%)	29/29
Non-haemophilia study group	NBA positive	12	1 (8%)	0	0	12/12

Samples were reviewed from: (i) The haemophilia reference group (a summary of previously published data for a group of 97 haemophilia A patients tested as part of the Hemophilia Inhibitor Research Study and used for reference); (ii) The haemophilia study group (the study group of 11 haemophilia patients listed in Table 4); and (iii) The non-haemophilia study group (the study group of 41 non-haemophilia patients with positive LA tests).